Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Anlotinib

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Early Phase 1 (1)
Phase 2 (1)
Phase 3 (1)

Trial Status

Recruiting1
Unknown1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT06327269Early Phase 1RecruitingPrimary

Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma

NCT02260505Phase 3Completed

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)

NCT05602415Phase 2Unknown

Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma

Showing all 3 trials

Research Network

Common Treatments

  • Anlotinib1
  • Lenvatinib1
  • Surgery1
  • Radiotherapy1

Active Sponsors

  • Chang Gung Memorial Hospital1
  • Centre Leon Berard1
  • Ministry of Health and Welfare, Taiwan1
  • Ruijin Hospital1

Top Investigators

Related Conditions

  • Anlotinib1
  • Radiotherapy1
  • Gastrointestinal Stromal Tumors1
  • Resected Gastrointestinal Stromal Tumors1
  • Kit Gene Mutation1

Activity Timeline